INfectious DIsease REgistry BIObank

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2044-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Priority Program-Bone Infection Registry

NCT01677000

Bone Infection Staphylococcus Aureus

COMPLETED

Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases

NCT04698148

Clostridium Difficile Infection Multi Drug Resistant Organisms Chronic Inflammatory Bowel Disease +2 more

COMPLETED

Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

NCT06833593

Enterococcus Faecalis Infection Blood Stream Infection Gut Microbiomes

RECRUITING

Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases

NCT04689074

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Advanced-Chronic Kidney Disease (CKD) Diabetic Kidney Disease (DKD) +1 more

COMPLETED

Prospective Study of Patients Treated for Bone and Joint Infection (BJI) Due to Staphylococcus Aureus, Aiming at Identifying Biomarkers of Diagnosis Interest in Chronic BJI

NCT04583241

Bone and Join Infection (BJI) Periprosthetic Joint Infection (PJI)

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The registry would provide a comprehensive database including a vast population of patients with infectious diseases, favoring the analysis of clinical, laboratory and therapeutic data of specific infectious conditions.

Specific infectious diseases of major interest include, among others:

* Bloodstream infections (i.e.: infectious syndromes manifesting with bacteremia)
* Endovascular infections (i.e.: infective endocarditis, cardiovascular implantable electronic device infections, vascular graft infections, etc.)
* Central nervous system infections (i.e.: meningitis, encephalitis, cerebral abscess, ventricular shunts infections, etc.)
* Bone and joint infections (i.e.: osteomyelitis, spondylodiscitis, prosthetic joint infections, etc.)
* Sexually transmitted infections (i.e.: gonococcal and non-gonococcal urethritis, proctitis, epididymo-orchitis, syphilis, etc.)
* HIV infection
* Emerging and re-emerging infectious diseases.

General objectives of the study for each specific infectious disease include:

* description and evolution over time of clinical and laboratory characteristics of patients with specific infectious diseases;
* description and evolution over time of microbial isolates, including antimicrobial susceptibility testing;
* description and evolution over time of treatment employed in patients with specific infectious diseases;
* evaluation of predictive factors for treatment success and mortality in patients with specific infectious diseases;
* description, evaluation and prognostic impact of microbial, immunological and inflammatory biomarkers.

The general study objectives, along with more specific objectives related to a specific infectious disease, will be evaluated in specific observational studies, nested within the Registry (i.e., using data and biosamples collected in the Registry with the potential addition of data obtained from investigations performed on available biological samples).

To achieve these objectives, participants are asked to donate biological samples (blood, cerebrospinal fluid, urine, other relevant biological samples related to the specific infectious disease, collected according to good clinical practice and available guidelines) for studies to identify modifiers of a specific infectious disease and to establish and validate biological markers tracking the progressive course of the considered disease, along with drug efficacy and toxicity.

The following clinical and laboratory data will be recorded at baseline and at follow-up visits:

* Age, measured in years
* Sex at birth (male, female)
* Comorbidities, measured with Charlson score (minimum 0 - maximum 37; higher scores linked to worse outcome)
* Source of infection, (central nervous system, respiratory tract, endovascular infection, intra-abdominal, urinary tract, skin and soft tissue, bone and joint, other).
* Sequential Organ Failure Assessment (SOFA) score (minimum 0 - maximum 24; higher scores linked to worse outcome)
* Pitt Score (minum 0 - maximum 14; higher scores linked to worse outcome)
* Length of hospital stay (days)
* Number of patients requiring Intensive care unit (ICU) admission, surgical interventions or other procedures
* Nerological impairment (Rankin scale \[minimum 0 - maximum 6; higher scores linked to worse outcome\])
* Functional impairment (Karnofsky scale \[minum 0 - maximum 100; higher scores linked to better outcome\])
* Results of routine laboratory tests
* Drug plasma concentrations
* Results of microbiological investigations (identification of the causative organisms, antimicrobial susceptibility testing results, mechanism of resistance)
* Results of imaging investigations
* Treatment strategies (type, dose, administration of antimicrobials)
* Development of drug toxicities
* Mortality (all-cause and infection-attributable)

Both data and biosamples will be collected starting from the baseline (BL) of the infectious disease after obtaining informed consent. Follow-up data and biosamples will be collected at the end of treatment (EOT) and at 6 months after the EOT for the specific condition or, in case of no therapeutic intervention, at 6 months after diagnosis. In patients with HIV infection follow-up data and biosamples will be collected yearly after baseline. Additional data and biosamples will be collected at other time-points according to the usual temporal evolution of specific diseases, and in case of relevant clinical events or therapeutic modification. All specimens will be collected according to good clinical practice and available national and international guidelines.

Data analysis will be performed by the investigators on approved proposals. Statistical methods will be defined as part of the proposals.

The variables of the study will be described using means or medians and 95% confidence intervals or interquartile ranges for continuous variables and proportions with their 95% confidence intervals for categorical variables.

Comparisons between groups will be made using the chi-square test or Fisher's exact test (categorical variables) or using the non-parametric Mann-Whitney test (continuous variables).

Significant variations in continuous variables over time may be assessed using t-tests for paired data o Wilcoxon ranks sign test (only two timepoints) o analysis of variance for repeated measures or linear mixed models (all timepoints available during follow-up).

The presence of linear relationships between continuous variables can be tested by means of Pearson correlation coefficients (parametric) or Spearman correlation coefficients (non-parametric).

Logistic regression models will be applied to determine the predictors of outcomes; the risks (odds ratios) and the corresponding 95% confidence intervals will be reported.

Cox regression models will be applied to determine predictors of outcomes; risks (odds ratios) and corresponding 95% confidence intervals will be reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bloodstream Infections Central Nervous System Infections Bone and Joint Infections Endovascular Infections Infective Endocarditis CIED-related Infections Vertebral Osteomyelitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with clinically suspected or microbiologically documented infectious diseases (bacterial, viral, fungal or parasitic);
* At least 18 years of age or older;
* Able to provide informed consent;
* Participants who are unable to understand the study protocol or are unable to give informed consent, but have a legal representative